Sight Sciences

Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. It also develops pharmaceuticals, drug delivery systems, and diagnostics for the treatment of ophthalmic conditions. The firm's products include viscosurgical system and trabeculotomy instruments. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sight Sciences reports stellar Q4 earnings, eyes sustainable growth

Sight Sciences delivered strong revenue growth in Q4 2022, driven by successful product offerings and market expansion efforts. While facing increased operating expenses and margin challenges, the company remains optimistic about achieving cash flow breakeven by 2025 and sustaining growth through innovative technologies and market strategies.

Sight Sciences excels in Q1 earnings, eyes growth opportunities

Sight Sciences' Q1 2023 performance reflects strong revenue growth, effective cost management, and a clear path towards achieving financial targets.
The company's leadership reinforcement, strategic focus on cash flow, and discussions on market trends position it well for future success.
While facing challenges in reimbursement changes and operational efficiency, Sight Sciences is poised to leverage opportunities for innovation and growth.

Sight Sciences excels in Q2 with record revenue and clinical validation

Sight Sciences demonstrated strong financial performance, highlighted by revenue growth and operational improvements. While facing challenges related to potential impacts on product sales and reimbursement discussions, the company remains optimistic about the growth prospects of its innovative technologies and reaffirmed its annual revenue guidance.

Sight Sciences reports Q3 revenue growth amidst operational improvements

Sight Sciences delivered solid financial performance in Q3, with revenue growth, margin improvement, and cost-saving measures
While facing challenges related to market access and revenue uncertainties, the company's strengths in innovation and efficiency position it well for future growth
Strategic opportunities in product development, market expansion, and operational optimization can drive sustained success and value creation for stakeholders

Sight Sciences posts successful Q4 results amidst revenue challenges

Sight Sciences reported strong financial performance in Q4 2023, with revenue growth, improved margins, and reduced expenses.
The company faces challenges in revenue decline for Q4, optimizing commercial strategies, and navigating reimbursement landscapes.
Opportunities lie in market expansion, revenue growth, reimbursement wins, and shifting treatment paradigms towards minimally invasive interventions.
Overall, Sight Sciences is well-positioned with a focus on innovation, clinical efficacy, and commercial strategies for 2024 opportunities.

Sight Sciences reports record Q1 revenue and eyes sustained growth

Sight Sciences posted strong financials with record revenue and improved cash usage.
Focused on driving growth in Surgical Glaucoma and addressing challenges in Dry Eye market.
Opportunities lie in market expansion, technology adoption, and sustained growth.
Company optimistic about achieving double-digit growth in the coming quarters.

Sight Sciences reports strong Q2 results, eyes growth opportunities ahead

Sight Sciences demonstrated robust financial and operational performance in Q2 2024, driven by revenue growth and improved cash management.
Strategic initiatives in surgeon training, product differentiation, and pricing reflect the company's focus on market expansion and value realization.
While facing challenges in revenue outlook and market dynamics, Sight Sciences remains poised to capitalize on growth opportunities in both Surgical Glaucoma and Dry Eye segments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Sight Sciences, Inc. (SGHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Sight Sciences, Inc. (SGHT) Rating Upgrade to Buy

Cigna has close to 15 million covered lives Cigna's Coverage Policy includes procedures enabled with OMNI ® Surgical System technology as medically necessary and covered MENLO PARK, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, announced today that Cigna Healthcare (“Cigna”), has updated its Glaucoma Surgical Procedure policy to cover both ab interno canaloplasty and goniotomy (trabeculotomy) procedures for the treatment of open-angle glaucoma effective June 15, 2023.

Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)

MENLO PARK, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces that Catherine Mazzacco was elected to the Company's board of directors at its Annual Meeting of Stockholders held on June 8, 2023. Ms. Mazzacco will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders.

Sight Sciences Announces Addition of New Director Catherine Mazzacco

Sight Sciences, Inc.'s share price has fallen by -13.3% in the past 3 weeks, despite reporting a narrower-than-expected net loss in Q1 and sticking to its 2023 guidance. Sight Sciences' key Q1 2023 metrics offered positive read-throughs for the company's growth prospects. I continue to rate Sight Sciences, Inc. stock as a Buy, as I view Sight's recent share price weakness and valuation discount to peers as unjustified.

Sight Sciences: Recent Stock Price Pullback Is Unwarranted

Retrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and clinically meaningful IOP reductions observed at 12 months persisted through 24 months Sustained and clinically meaningful reductions in glaucoma medication use observed at 12 months also persisted through 24 months Confirmed safety and efficacy of OMNI Surgical System technology in both standalone and combination cataract procedures Longest published multicenter clinical results of OMNI Surgical System to date MENLO PARK, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the publication of two-year results of the ROMEO (Retrospective, Observational, Multicenter, Evaluation of OMNI) study in Clinical Ophthalmology.

Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical Syste

The average of price targets set by Wall Street analysts indicates a potential upside of 38.8% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Sight Sciences, Inc. (SGHT)? Wall Street Analysts Think 38.78%

Sight Sciences, Inc. (NASDAQ:SGHT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Ali Bauerlein - Chief Financial Officer Tom Huang - Head of Corporate Strategy Conference Call Participants Phillip Dantoin - Piper Sandler Thomas Stephan - Stifel Michael Arens - William Blair Operator Good day and thank you for standing by. Welcome to the Sight Sciences First Quarter 2023 Earnings Results Call.

Sight Sciences, Inc. (SGHT) Q1 2023 Earnings Call Transcript

Patients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract surgery alone Patients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract surgery alone

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.49 per share a year ago.

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates

MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced plans to present at the upcoming Bank of America Securities 2023 Health Care Conference in Las Vegas, NV.

Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference

MENLO PARK, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 4, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023

The event will include presentations from leading glaucoma surgeons and remarks from the Sight Sciences executive management team The event will include presentations from leading glaucoma surgeons and remarks from the Sight Sciences executive management team

Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023

Sight Sciences, Inc. (SGHT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength?

MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison “Ali” Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023.

Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

MENLO PARK, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today reported that it defeated all four patent invalidity challenges filed by Alcon and Ivantis in the United States Patent and Trademark Office.

Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office

Sight Sciences, Inc. (NASDAQ:SGHT ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Chief Executive Officer Jim Rodberg - Interim Chief Financial Officer Tom Huang - Head of Corporate Strategy Conference Call Participants Thomas Stephan - Stifel Financial Corp. Craig Bijou - Bank of America Securities, Inc. Joanne Wuensch - Citi Cecilia Furlong - Morgan Stanley Margaret Kaczor - William Blair Matthew O'Brien - Piper Sandler David Saxon - Needham & Company Operator Hello, and welcome to Sight Sciences Fourth Quarter 2022 Earnings Results. At this time, all participants are in listen-only mode.

Sight Sciences, Inc. (SGHT) Q4 2022 Earnings Call Transcript

MENLO PARK, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and year ended December 31, 2022 and issued financial guidance for the year ending December 31, 2023.

Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results

The Ergo-Series maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures The Ergo-Series maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures

Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System

MENLO PARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022, after the market close on Monday, March 13, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

MENLO PARK, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced plans to present at the upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York, NY.

Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference

BioMarin Pharmaceutical

CRISPR Therapeutics

These three companies are attractive targets for their potential.

3 Prime Healthcare Takeover Targets

Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD) Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD)

Sight Sciences Announces 1,000th TearCare® Customer Installation

Company Also Announces CFO Transition Company Also Announces CFO Transition

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results

Glaucoma Qdata Contains More than 341,000 MIGS Records with Nearly Three Years of Patient Follow-Up SAN FRANCISCO and MENLO PARK Calif. , Jan. 4, 2023 /PRNewswire/ --  Verana Health ®—a digital health company elevating quality in real-world data (RWD)—and Sight Sciences , Inc. (NASDAQ: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced a research collaboration designed to provide insights that may lead to improved outcomes for patients with primary open-angle glaucoma (POAG).

Verana Health and Sight Sciences Collaborate on Glaucoma Research Using Curated Real-World Data from the IRIS Registry

MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, is pleased to report independent data addressing a frequent question from eyecare practitioners (ECPs) and patients regarding the treatment of meibomian gland disease (MGD) using the TearCare ® System: How long does a single treatment last?

News for Sight Sciences Stock (SGHT)